• iron ion binding • oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen • (S)-limonene 6-monooxygenase activity • (S)-limonene 7-monooxygenase activity • heme binding • metal ion binding
Cytochrome P450 2C9 (abbreviated CYP2C9), a member of the cytochrome P450 mixed-function oxidase system, is involved in the metabolism of xenobiotics in the body. It is involved in the metabolism of several important groups of drugs including many non-steroidal anti-inflammatory drugs (NSAIDs) and sulfonylureas.
Genetic polymorphism exists for CYP2C9 expression, with approximately 1–3% of Caucasian populations being poor metabolisers with no CYP2C9 function.
^ Where classes of agents are listed, there may be exceptions within the class
^ ab Mentioned both in the reference named FASS and were previously mentioned in Wikipedia. Further contributions may follow other systems
^ Swedish environmental classification of pharmaceuticals Facts for prescribers (Fakta för förskrivare)
Goldstein JA, de Morais SM (1995). "Biochemistry and molecular biology of the human CYP2C subfamily.". Pharmacogenetics4 (6): 285-99. PMID 7704034.
Miners JO, Birkett DJ (1998). "Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.". British journal of clinical pharmacology45 (6): 525-38. PMID 9663807.
Smith G, Stubbins MJ, Harries LW, Wolf CR (1999). "Molecular genetics of the human cytochrome P450 monooxygenase superfamily.". Xenobiotica28 (12): 1129-65. PMID 9890157.
Henderson RF (2001). "Species differences in the metabolism of olefins: implications for risk assessment.". Chem. Biol. Interact.135-136: 53-64. PMID 11397381.
Xie HG, Prasad HC, Kim RB, Stein CM (2003). "CYP2C9 allelic variants: ethnic distribution and functional significance.". Adv. Drug Deliv. Rev.54 (10): 1257-70. PMID 12406644.
Palkimas MP, Skinner HM, Gandhi PJ, Gardner AJ (2004). "Polymorphism induced sensitivity to warfarin: a review of the literature.". J. Thromb. Thrombolysis15 (3): 205-12. doi:10.1023/B:THRO.0000011376.12309.af. PMID 14739630.
Daly AK, Aithal GP (2004). "Genetic regulation of warfarin metabolism and response.". Seminars in vascular medicine3 (3): 231-8. doi:10.1055/s-2003-44458. PMID 15199455.
García-Martín E, Martínez C, Ladero JM, Agúndez JA (2007). "Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals.". Molecular diagnosis & therapy10 (1): 29-40. PMID 16646575.